Li Hui, Guo Ruhai, Jia Yanqing, Zhang Xiao, Liu Zishan, Shi WenLi, Hu Ruochen, Zhang YiNing, Nasir Saba, Han Likang, Qiu Xinxin, Wang Xinglong
College of Veterinary Medicine, Northwest A&F University, Yangling, Shanxi, China.
Department of Animal Engineering/Engineering Research Center of Animal Disease Prevention and Control, Universities of Shaanxi Province, Yangling Vocational and Technical College, YangLing, Shaanxi Province, China.
Transbound Emerg Dis. 2025 Jul 16;2025:3628600. doi: 10.1155/tbed/3628600. eCollection 2025.
African Swine Fever (ASF) is a highly lethal viral disease in swine. The emergence and rapid spread of African Swine Fever virus (ASFV) in China, since 2018 have caused significant economic losses to the pig farming industry. The complexity of ASFV has impeded the development of effective vaccines, and with no commercial vaccines currently available in China, highlighting the urgent need for safe and efficacious vaccine candidates. In this study, we utilized a highly immunogenic quadruple-gene-deleted recombinant pseudorabies virus (PRV) strain (rPRV SX-10ΔUL24/TK/gI/gE) as a vector to construct two recombinant viral strains expressing ASFV p54, p72, CD2v, and pp62 proteins using the HDR-CRISPR/Cas9 system. These strains, rPRV-p54+p72 and rPRV-CD2v+pp62, demonstrated stable genetic characteristics and efficiently expressed and delivered heterologous proteins while maintaining biological properties similar to their parental strain. Safety evaluation revealed that both recombinant strains exhibited favorable safety profiles in immunized mice and piglets. Furthermore, the strains induced robust humoral and cellular immune responses, as evidenced by specific antibody enzyme-linked immunosorbent assay (ELISA), lymphocyte proliferation assays, and analysis of CD3+, CD4+, and CD8+ T lymphocytes. These findings suggest that rPRV-p54+p72 and rPRV-CD2v+pp62 are promising bivalent vaccine candidates for protecting against both PRV and ASFV infections.
非洲猪瘟(ASF)是猪的一种高致死性病毒病。自2018年以来,非洲猪瘟病毒(ASFV)在中国的出现和迅速传播给养猪业造成了重大经济损失。ASFV的复杂性阻碍了有效疫苗的研发,且目前中国尚无商业疫苗可用,这凸显了对安全有效的候选疫苗的迫切需求。在本研究中,我们利用一种高免疫原性的四重基因缺失重组伪狂犬病病毒(PRV)株(rPRV SX-10ΔUL24/TK/gI/gE)作为载体,使用HDR-CRISPR/Cas9系统构建了两种表达ASFV p54、p72、CD2v和pp62蛋白的重组病毒株。这些毒株,即rPRV-p54+p72和rPRV-CD2v+pp62,表现出稳定的遗传特性,能有效表达和递送异源蛋白,同时保持与其亲本毒株相似的生物学特性。安全性评估显示,两种重组毒株在免疫小鼠和仔猪中均表现出良好的安全性。此外,通过特异性抗体酶联免疫吸附测定(ELISA)、淋巴细胞增殖测定以及CD3+、CD4+和CD8+ T淋巴细胞分析证明,这些毒株诱导了强烈的体液免疫和细胞免疫反应。这些发现表明,rPRV-p54+p72和rPRV-CD2v+pp62是有望用于预防PRV和ASFV感染的二价候选疫苗。